Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) FCF Margin (2019 - 2025)

Revolution Medicines (RVMD) has 6 years of FCF Margin data on record, last reported at 1732.74% in Q3 2025.

  • For Q3 2025, FCF Margin changed N/A year-over-year to 1732.74%; the TTM value through Dec 2025 reached 7872.04%, changed N/A, while the annual FY2023 figure was 3094.14%, 245587.0% down from the prior year.
  • FCF Margin reached 1732.74% in Q3 2025 per RVMD's latest filing, up from 16560.65% in the prior quarter.
  • Across five years, FCF Margin topped out at 1732.74% in Q3 2025 and bottomed at 16560.65% in Q4 2023.
  • Average FCF Margin over 4 years is 2116.41%, with a median of 695.86% recorded in 2022.
  • Peak YoY movement for FCF Margin: surged 187226bps in 2022, then crashed -1616630bps in 2023.
  • A 4-year view of FCF Margin shows it stood at 427.57% in 2021, then grew by 8bps to 394.34% in 2022, then crashed by -4100bps to 16560.65% in 2023, then surged by 110bps to 1732.74% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 1732.74% in Q3 2025, 16560.65% in Q4 2023, and 1788.89% in Q2 2023.